Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 28, 2016 09:05 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections

JERSEY CITY, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast...
December 01, 2015 17:09 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis

JERSEY CITY, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has initiated enrollment and the first group of patients have been...
November 13, 2015 09:03 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update

JERSEY CITY, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended September 30, 2015, and provided an...
November 12, 2015 08:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078

JERSEY CITY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the initiation of a Phase 1 clinical trial to study the intravenous (IV)...
November 02, 2015 17:25 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Appoints Eric Francois as Chief Financial Officer

JERSEY CITY, N.J., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Eric Francois as Chief Financial Officer,...
October 07, 2015 16:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Appoints Rajeshwar Motheram as Vice President, Pharmaceutical Development

- Strengthens Management Team with the Addition of Pharmaceutical Development Expertise - - Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) - JERSEY CITY, N.J., Oct. 7, 2015 (GLOBE...
September 28, 2015 16:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Announces Board of Directors Transitions

JERSEY CITY, N.J., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the following changes to its Board of Directors: Edward...
September 21, 2015 08:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015

JERSEY CITY, N.J., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company's...
September 10, 2015 08:30 ET | Source: SCYNEXIS, Inc.

SCYNEXIS to Present Data at ICAAC/ICC 2015 for Novel Antifungal Drug Candidate

JERSEY CITY, N.J., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced one podium and three poster presentations related to...
August 19, 2015 18:00 ET | Source: SCYNEXIS, Inc.

SCYNEXIS, Inc. Reports Second Quarter 2015 Financial Results

RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the second quarter of...